VistaGen Therapeutics Inc (VTGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $8.01M
Last updated: Nov 17, 2026 at 4:15 PM ET
VistaGen Therapeutics Inc (VTGN) Statistics
VistaGen Therapeutics (VTGN) has a market cap of $8.01M. It kept -2475.56% of revenue as net income over the last 12 months. Revenue grew 230.24% over the last 12 months from the 12 months before.
Total Valuation
| Market Cap | $8.01M |
|---|---|
| Latest price (Nov 17, 2026) | $0.19 |
Key Dates
The next earnings report is expected on Feb 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 13, 2026 |
| Fiscal Year End | March |
Valuation Ratios
Sales and book value multiples are 3.5x and 0.6x. Its year-end P/S ranged from 7.6x to 375.7x from 2017 to 2025.
| P/S Ratio | 3.5x |
|---|---|
| Forward P/S | 4.7x |
| P/B Ratio | 0.6x |
Price Statistics
The stock is down 95.05% over 52 weeks and trades 13.64% below its 50-day average.
| Beta (1Y) | 1.88 |
|---|---|
| 52-Week Change | -95.05% |
| 1-Month Change | -7.43% |
| 3-Month Change | -22.98% |
| 6-Month Change | -70.16% |
| 5-Year Change | -99.76% |
| 10-Year Change | -99.86% |
| Total Return (1Y) | -95.05% |
| Total Return (3Y CAGR) | -61.82% |
| Total Return (5Y CAGR) | -69.06% |
| Max Drawdown (1Y) | -96.66% |
| Max Drawdown (3Y) | -97.16% |
| Sharpe Ratio (1Y) | -1.46 |
| Correlation with SPY (1Y) | 0.12 |
| 50-Day Average | $0.22 |
| 200-Day Average | $0.42 |
| 52-Week Range | $0.16 to $5.14 |
| RSI (14 Days) | 47.5 |
| Average Volume (20 Days) | 757.73K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.64x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 2.64x |
|---|---|
| Quick Ratio | 2.64x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -393.16% and return on assets is -251.67% over the last 12 months.
| Return on Equity (ROE) | -393.16% |
|---|---|
| Return on Assets (ROA) | -251.67% |
| Asset Turnover | 0.05x |
Scores
VTGN has an Altman Z-Score of -37.08, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -37.08 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $2.38M over the last 12 months.
| Revenue | $2.38M |
|---|---|
| Revenue Growth (YoY) | +230.24% |
| Gross Profit | $2.38M |
| Operating Income | -$60.55M |
| Pretax Income | -$58.94M |
| Net Income | -$58.94M |
| Reported EPS (TTM) | -$1.36 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 64.01% of the $23.42M in total assets.
| Cash and Equivalents | $10.89M |
|---|---|
| Total Debt | $0 |
| Net Cash | $10.89M |
| Net Cash Per Share | $0.25 |
| Working Capital | $13.87M |
| Shareholder Equity | $14.99M |
| Book Value Per Share | $0.34 |
| Total Assets | $23.42M |
| Total Liabilities | $8.43M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$60.70M |
|---|---|
| FCF Per Share | -$1.37 |
| Depreciation and Amortization | $769.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -2543.22%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -2543.22% |
| Pretax Margin | -2475.26% |
| Net Margin | -2475.56% |
Growth
| Revenue Growth (5Y CAGR) | +3.10% |
|---|---|
| Book Value Per Share Growth (2Y CAGR) | -53.03% |
| Tangible Book Per Share Growth (2Y CAGR) | -53.03% |
Dividends and Yields
VTGN does not pay a dividend.
| Buyback Yield | -44.80% |
|---|---|
| Shareholder Yield | -44.80% |
Stock Splits
The last split was a 1-for-30 reverse split on Jun 7, 2023.
| Last Split Date | Jun 7, 2023 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:30 |
Analyst Forecast
Consensus estimates put revenue growth at 33.96% a year over the next fiscal year.
| Revenue Growth Forecast (1Y CAGR) | +33.96% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About VTGN
What is VTGN's market cap?
VistaGen Therapeutics has a market cap of $8.01M.
How many shares of VTGN are outstanding?
VistaGen Therapeutics has 44.44M shares outstanding. The count is up 24.31% from a year earlier.
Does VTGN pay a dividend?
No. VistaGen Therapeutics does not pay a dividend.
How much debt does VTGN have?
VistaGen Therapeutics has $0 of total debt and $10.89M of cash and equivalents, a net cash position of $10.89M.
VTGN pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors